BRPI0508364A - derivados de 4-benzimidazol-2-ilpiridazin-3-ona - Google Patents

derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Info

Publication number
BRPI0508364A
BRPI0508364A BRPI0508364-8A BRPI0508364A BRPI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A
Authority
BR
Brazil
Prior art keywords
benzimidazol
compounds
derivatives
ylpyridazin
kinase inhibitors
Prior art date
Application number
BRPI0508364-8A
Other languages
English (en)
Inventor
Swen Hoelder
Karl Schoenafinger
David William Will
Hans Matter
Guenther Mueller
Cecile Combeau
Christine Delaisi
Anke Steinmetz
Ingrid Sassoon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0508364A publication Critical patent/BRPI0508364A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE 4-BENZIMIDAZOL-2-ILPIRIDAZIN-3-ONA. A presente invenção refere-se a compostos da fórmula geral (l), onde a definição dos substituintes A, B, D, E, R¬ 1¬ e R¬ 2¬ são detalhadas na descrição, e os seus sais fisioligicamente tolerados, a um processo para a preparação destes compostos e a seu uso como produtos farmacêuticos. Estes compostos são inibidores de quinase, em particular inibidores da quinase CDK2 (quinase 2 dependente de ciclina).
BRPI0508364-8A 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona BRPI0508364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004010207A DE102004010207A1 (de) 2004-03-02 2004-03-02 Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
PCT/EP2005/002569 WO2005085231A1 (en) 2004-03-02 2005-02-18 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives

Publications (1)

Publication Number Publication Date
BRPI0508364A true BRPI0508364A (pt) 2007-07-24

Family

ID=34853913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508364-8A BRPI0508364A (pt) 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Country Status (14)

Country Link
US (2) US7470689B2 (pt)
EP (1) EP1723137A1 (pt)
JP (1) JP4792455B2 (pt)
KR (1) KR20070008582A (pt)
CN (1) CN101061108A (pt)
AR (1) AR047987A1 (pt)
AU (1) AU2005219563A1 (pt)
BR (1) BRPI0508364A (pt)
CA (1) CA2555161A1 (pt)
DE (1) DE102004010207A1 (pt)
IL (1) IL177204A0 (pt)
TW (1) TW200538452A (pt)
UY (1) UY28783A1 (pt)
WO (1) WO2005085231A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3283475B1 (en) * 2015-04-16 2019-10-16 Merck Patent GmbH 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324580A1 (de) 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
JP2002511887A (ja) * 1997-08-22 2002-04-16 アボツト・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害薬
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
MXPA02000120A (es) * 1999-06-28 2002-07-02 Janssen Pharmaceutica Nv Inhibidores de la replicacion del virus sincitial respiratorio.
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
CA2442428A1 (en) * 2001-03-28 2002-10-10 Mark D. Wittman Novel tyrosine kinase inhibitors
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
CN1245389C (zh) 2001-07-27 2006-03-15 山之内制药株式会社 芳基乙烯磺酰胺衍生物的新型结晶及其制造方法
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005519895A (ja) 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
AU2003221500B9 (en) 2002-02-28 2008-11-20 Mitsubishi Pharma Corporation Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
HU227255B1 (en) * 2002-04-26 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
RU2339624C2 (ru) 2002-12-12 2008-11-27 Авентис Фарма С.А. Производные аминоиндазолов и их применение в качестве ингибиторов киназ
IL157751A0 (en) 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
BRPI0408359A (pt) * 2003-03-18 2006-03-21 Kowa Co derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US7232939B2 (en) 2004-05-28 2007-06-19 E.I. Du Pont De Nemours And Company Nucleic acid molecules encoding cyclotide polypeptides and methods of use
ES2326280T3 (es) 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
US7232901B2 (en) 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
US20090042880A1 (en) 2009-02-12
US20070173503A1 (en) 2007-07-26
TW200538452A (en) 2005-12-01
US7754713B2 (en) 2010-07-13
JP2007531712A (ja) 2007-11-08
UY28783A1 (es) 2005-09-30
CA2555161A1 (en) 2005-09-15
IL177204A0 (en) 2006-12-10
CN101061108A (zh) 2007-10-24
KR20070008582A (ko) 2007-01-17
DE102004010207A1 (de) 2005-09-15
JP4792455B2 (ja) 2011-10-12
AR047987A1 (es) 2006-03-15
US7470689B2 (en) 2008-12-30
WO2005085231A1 (en) 2005-09-15
EP1723137A1 (en) 2006-11-22
AU2005219563A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0510410A (pt) compostos orgánicos
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0512797A (pt) derivados de quinazolinona como inibidores de parp
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0607577A2 (pt) antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0817843B8 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR9909688A (pt) Indolinonas substituìdas, a sua preparação e seu uso como composições farmacêuticas
BRPI0510409A (pt) heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0911161B8 (pt) derivados de piridazinona e seu processo de preparação
BRPI0514091A (pt) 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.